Short-Term Fasting Alters Cytochrome P450–Mediated Drug Metabolism in Humans

Laureen A. Lammers, Roos Achterbergh, Emmely M. de Vries, F. Samuel van Nierop, Heinz-Josef Klümper, Maarten R. Soeters, Anita Boelen, Johannes A. Romijn, and Ron A. A. Mathôt

ABSTRACT

Experimental studies indicate that short-term fasting alters drug metabolism. However, the effects of short-term fasting on drug metabolism in humans need further investigation. Therefore, the aim of this study was to evaluate the effects of short-term fasting (36 h) on P450-mediated drug metabolism. In a randomized crossover study design, nine healthy subjects ingested a cocktail consisting of five P450-specific probe drugs [caffeine (CYP1A2), S-warfarin (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4)] on two occasions (control study after an overnight fast and after 36 h of fasting). Blood samples were drawn for pharmacokinetic analysis using nonlinear mixed effects modeling. In addition, we studied in Wistar rats the effects of short-term fasting on hepatic mRNA expression of P450 isoenzymes corresponding with the five studied P450 enzymes in humans. In the healthy subjects, short-term fasting increased oral caffeine clearance by 20% ($P < 0.03$) and decreased oral S-warfarin clearance by 25% ($P < 0.001$). In rats, short-term fasting increased mRNA expression of the orthologs of human CYP1A2, CYP2C19, CYP2D6, and CYP3A4 ($P < 0.05$), and decreased the mRNA expression of the ortholog of CYP2C9 ($P < 0.001$) compared with the postabsorptive state. These results demonstrate that short-term fasting alters cytochrome P450–mediated drug metabolism in a nonuniform pattern. Therefore, short-term fasting is another factor affecting cytochrome P450-mediated drug metabolism in humans.

Introduction

There is considerable variability in the rate of drug metabolism due to physiologic, genetic, pharmacologic, environmental, and nutritional factors (Ingelman-Sundberg, 2001). Nutritional factors modulate the activity of many enzyme systems in the liver that play an important role in the metabolism and elimination of drugs (Murray, 2006). Interestingly, only a few studies are available in humans describing the role of short-term fasting on the activity of certain individual liver enzymes (O’Shea et al., 1994). However, the effect of fasting on human drug metabolism in general, and on cytochrome P450 (P450) enzymes that are predominantly involved in human drug metabolism (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) in particular, has not been studied in detail. Studies in animals indicate that short-term fasting alters drug metabolism (Qu et al., 1998; Longo et al., 2000; Murray, 2006; Merrell and Cherrington, 2011). Therefore, short-term fasting may contribute to both intra- and interindividual variations in drug metabolism. Moreover, fasting-related consequences such as malnutrition or cachexia are common in patients. For example, the prevalence of cachexia ranges from about 10% in patients with chronic heart failure or chronic obstructive pulmonary disease to about 70% in patients with advanced cancer (von Haehling and Anker, 2010). Changes in drug metabolism due to alterations in nutritional conditions may potentially result in treatment failure or, conversely, in untoward side effects.

The effects of fasting on drug metabolism in experimental models can be explained by the altered activity of nuclear transcription factors. The nuclear receptors pregnane X receptor (PXr) and constitutive androstane receptor (CAR) (Klein et al., 1993) serve as xenosensors, which regulate the activity of many of the drug-metabolizing P450 enzymes in animals (Hernandez et al., 2009). Interestingly, short-term fasting increases the activity of both constitutive androstane receptor (CAR) and PXr (Ding et al., 2006; Hernandez et al., 2009). However, the mechanisms regulating nuclear transcription factors are complex, and fasting can also attenuate PXr function, as studied by Buler et al. (2011). Because the activities of CAR and PXr are altered by fasting and both transcription factors are involved in the regulation of drug metabolism in animals, we hypothesized that short-term fasting influences drug metabolism in humans as well.

Therefore, the aim of our study was to assess the effect of short-term fasting on the pharmacokinetics of five different drugs, metabolized via specific metabolic cytochrome P450 pathways by using a cocktail approach in healthy male subjects. To gain more insight into the effect of short-term fasting on P450-enzyme activity, the second aim of our study was to assess the effects of fasting on hepatic mRNA expression of PXr, CAR, and P450 enzymes (CYP1A2, 2C11, 2D2, and 3A2) in rats, which correspond to the five studied P450 enzymes in the healthy human subjects (CYP1A2, 2C9, 2C19, 2D6, and 3A4, respectively) (Martignoni et al., 2006).

L.A.L. and R.A. contributed equally to this work.

dx.doi.org/10.1124/dmd.114.062299

ABBREVIATIONS: AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; CI, confidence interval; CL/F, oral clearance; P450, cytochrome P450; LLOQ, lower limit of quantification; MLOQ, method limit of quantification; MS/MS, tandem mass spectrometry; MTT, mean transit time; NONMEM, nonlinear mixed effects modeling; OFV, objective function value; PK, pharmacokinetic; PXr, pregnane X receptor; ULOQ, upper limit of quantification; V/F, volume of distribution; VP, volume of plasma; VT, volume of tissue.
Human Study

Subjects. Male subjects were eligible to participate in the study if they were ≥ 18 years old, healthy as determined by an experienced physician, and with renal and liver function tests without clinically relevant abnormality. Only males were included because the hormonal status may affect hepatic enzyme function in women (Waxman and Holloway, 2009). Subjects were excluded if they had major illness in the past 3 months. Other exclusion criteria were as follows: gastrointestinal disease that may influence drug absorption; abnormal values of aspartate aminotransferase (IBer et al., 2001), alanine aminotransferase, bilirubin, γ-glutamyl transferase, alkaline phosphatase, and creatinine; drugs of abuse or excessive alcohol intake (>3 units of alcohol per day); use of alcohol for at least 2 days prior to each study day; strenuous exercise at least 3 days prior to each study day, defined as more than 1 hour of exercise per day; use of prescription or nonprescription drugs; consumption of caffeine-containing foods or beverages within 1 day prior to study; and consumption of grapefruit and grapefruit-containing products or starfruit for at least 2 days prior to each study day.

The study design was approved by the institutional ethics review board (ABRnr:NL40834.018.12). All subjects provided written informed consent before study entry, and the study was conducted in accordance with the ethical standard of the responsible committee on human experimentation and with the Helsinki Declaration of 1975 (as revised in 2008).

Experimental Design. We designed an open-label, single-dose crossover intervention study. Subjects were randomly assigned for receiving a single oral administration of a drug cocktail on two occasions with a washout period of 4 weeks. In both study occasions, the drug cocktail was administered at 8:00 AM. In the control study, the subjects were fasting from 10:00 PM the preceding evening to minimize the effect of food intake in the morning on the bioavailability of the drug cocktail. In the fasting study, the same subjects were fasting from 8:00 PM starting two evenings prior to the study, ensuring a duration of fasting of 36 hours at the moment the drug cocktail was administered. This period of fasting results in major changes in lipid metabolism (Klein et al., 1993; Soeters et al., 2012).

At noon, on both study occasions, the subjects were allowed to have a meal. To prevent differences in caloric intake between the two interventions to affect the pharmacokinetics of the drug cocktail, subjects consumed a standard fluid meal (NutraDrink Compact; Nutricia, Zoetermeer, The Netherlands) containing 25% of their estimated daily energy expenditure (25 kcal/kg/d). After another 4 hours, subjects were allowed to consume their habitual diet.

To standardize the 3 days preceding each study day, subjects were asked to keep a diary containing dietary instructions. Furthermore, adherence to the fasting period was checked by measuring the following biomarkers at baseline of both occasions: glucose, free fatty acids, β-hydroxybutyrate, and acetacetate (Foster et al., 1978). Differences in biochemical parameters between both interventions were tested using a paired t test for normally distributed data and a Wilcoxon signed-ranks test for data that were not distributed normally. The normality of data distribution was assessed using the Shapiro-Wilk test. P < 0.05 was considered significant. Statistical analysis was performed using IBM SPSS Statistics version 21.0.

A validated P450-probe drug probe cocktail was administered consisting of 100 mg caffeine (CYP1A2) (10 mg/ml ampoules; VUMC, Amsterdam, The Netherlands), 5 mg racemic warfarin (CYP2C9) (5 mg tablet; Crescent Pharma, Hampshire, UK), 20 mg omeprazole (CYP2C19) (20 mg capsule; Teva Pharmacemie, Haarlem, The Netherlands), 100 mg metoprolol (CYP2D6) (100 mg tablet; Teva Pharmacemie), and 0.03 mg/kg midazolam (CYP3A4) (1 mg/ml oral solution; UMCG, Groningen, The Netherlands) (Turpault et al., 2009).

Serial blood samples for calculation of pharmacokinetic (PK) parameters were collected after administration of the drug cocktail at t = 0, t = 1, t = 2, t = 3, t = 4, t = 5, t = 6, t = 7, t = 8, and t = 10 hours. Furthermore, PK samples at days 2, 3, 8, and 15 were obtained of which the latter two were due to the long elimination half-life of warfarin. Plasma was separated by centrifugation and stored at −80°C until analysis.

Bioanalysis of the P450-Probe Drugs. A liquid chromatography/tandem mass spectrometry method for the simultaneous determination of plasma concentrations of the five drugs used in the P450-probe cocktail was developed and validated. In brief, samples were deproteinized by a solution containing 420:80 acetonitrile:methanol and spiked with internal standards (caffeine-D9, omeprazole-D3, warfarin-D5, metoprolol-D7, and midazolam-D5). Chromatography was performed on a Shimadzu LC-30 Nexera HPLC system (Shimadzu, Kyoto, Japan) using Thermo Scientific Hypersil Gold HPLC column (50 mm × 2.1 mm, 1.9 μm) (Thermo Fisher Scientific, Waltham, MA). This was coupled to a 5500 QTrap mass spectrometer (ABSciex, Framingham, MA). The tandem mass spectrometry (MS/MS) system was operated using an electrospray in positive ionization mode. A three-component mobile phase contained the following: solvent A [ultrapure water (Purelab option-Q)], solvent B (Acetonitrile; Biosolve), and solvent C [2% formic acid/1% ammonium formate in water (Merck/Fukuda)]. A gradient of solvent B from 2 to 90% over 4 minutes was applied on the column and then cycled back to the initial condition. For the chiral compound S-warfarin, an Astec Chirobiotic V column (150 mm × 2.1 mm, 5 μm) was used, and the MS/MS system was operated using an electrospray in negative ionization mode. The same three-component mobile phase was used, but with a gradient of solvent B on the column from 5 to 40% in 3.5 minutes, directly followed by 90%, and then cycled back to 5%. For both columns, the temperature was maintained at 40°C and the autosampler temperature was kept at 10°C. The lower and upper limits of quantification (LLOQ and ULOQ) were 50–5000 ng/ml for caffeine, 1–200 ng/ml for metoprolol, 0.5–100 ng/ml for midazolam, 2–500 ng/ml for omeprazole, and 4–1000 ng/ml for S-warfarin. Linearity was R² ≥ 0.996 for all components except for S-warfarin (R² = 0.9954). Accuracy was within the ranges of 80–120% for LLOQ and 85–115% for the method limit of quantification (MLOQ) and ULOQ. Also, the within-run and between-run precision fall within the predefined maximum criteria (relative standard deviation LLOQ ≥ 20%, MLOQ and ULOQ ≤ 15%).

PK Data Analysis. For each P450-probe drug plasma concentration time curves from all subjects were analyzed simultaneously using nonlinear mixed effects modeling software (NONMEM version 7.1.2; Globomax, Ellicott City, MD). Nonlinear mixed effects compartmental modeling was preferred instead of noncompartmental data analysis because of the ability to accurately study time-dependent effects of fasting on the pharmacokinetics of the probe drugs.

Structural Model Development. Concentration data were log transformed for all compounds. The population models were built in a stepwise manner. Several compartment models with first-order elimination were evaluated. Model parameters were quantified as oral clearance (CL/F), intercompartment clearance, volume of distribution of the central (V1/F), and peripheral compartment (V2/F). For all the compounds, with the exception of omeprazole, the absorption rate constant (Ka) and lag time could not be estimated; respective values were fixed to 6 hours−1 and 0 hour. For omeprazole transit compartments were incorporated in the model to account for the delay between drug administration and absorption from the gut (Savic et al., 2007). The mean transit time (MTT) between the gut and systemic circulation was estimated by dividing the ratio of the number of oral doses administered (N) by the transition rate constant (Kw) between the compartments (MTT = n/Kw).

Inter- and intraindividual variability of the PK parameters was estimated using an exponential error model. For example, clearance in the ith individual was estimated using

\[
\frac{CL}{F} = \frac{CL}{F}_{\text{pop}} \times e^{(\eta_i - \mu)}
\]

where CL/F is the oral clearance for the ith individual on the jth occasion, CL/Fpop represents the population value, and \(\eta_i\) and \(\mu\) represent the interindividual and intraindividual random effects with mean 0 and the respective variances \(\sigma^2\) and \(\sigma^2\). The difference between the \(k_{\text{obs}}\) observed concentration of the ith individual (Cobs,k) and its corresponding model-predicted concentration (Cpred,k) was estimated with an additional error model

\[
\ln \left( \frac{\text{Cobs,k}}{\text{Cpred,k}} \right) = \ln (\text{CLpred,k}) + \epsilon_{k}
\]

where \(\epsilon\) is the residual random error with mean 0 and variance \(\sigma^2\). The statistical package R, version 64 3.0.1 (The R Foundation for Statistical Computing), and Xpose version 4 were used for dataset checkout, exploration, and model diagnostics (Jonsson and Karlsson, 1999). Pirana software was used as an interface between NONMEM, R, and Xpose (Keizer et al., 2011). Model diagnostics was based on the objective function values, precision of the parameter estimates, goodness-of-fit plots (plots of measured drug concentrations.
versus population or individual predictions, and conditional weighted residuals versus time and population-predicted) and shrinkage, which was calculated for all random effects (Karlsson and Savic, 2007).

**Covariate Analysis.** Correlations between fasting and PK parameters were evaluated by stepwise inclusion in the models (Mandema et al., 1992). For instance, the change of clearance due to fasting was evaluated using the following equation:

\[
\frac{CL}{F_i} = \frac{CL}{F_{pop} \times \theta_{fasting}}
\]

where \(\theta_{fasting}\) is the fractional change of clearance due to fasting.

To evaluate a possible time dependency of the effect of fasting on the pharmacokinetics of the studied compounds, a time cut point covariate model was used, as follows:

\[
\frac{CL}{F_i} = \frac{CL}{F_{pop}} \quad \text{for} \quad TIME \leq \theta_{cut}
\]

\[
\frac{CL}{F_i} = \frac{CL}{F_{pop}} \quad \text{for} \quad TIME > \theta_{cut}
\]

in which the PK parameter is increased or decreased before the time cut point \(\theta_{cut}\) and comparable with control after \(\theta_{cut}\).

The selection of covariates was carried out using a forward and backward selection approach.

**Model Validation.** The stability and performance of the final model were checked using simulation-based diagnostics (visual predictive checks) and bootstrap diagnostics (Ette, 1997). Bootstrapping was performed using the Perl bootstrap diagnostics (Ette, 1997; Bergstrand et al., 2011). Via the bootstrap re-checks in which simulated data exhibited a central tendency and validation of the models was further demonstrated by visual predictive checks in which the PK parameter is increased or decreased before the time cut point and comparable with control after \(\theta_{cut}\). The selection of covariates was carried out using a forward and backward selection approach.

**Statistical Analysis (Animal Study).** Data are expressed as means ± S.D. Differences in means were tested by one-way analysis of variance. For \(P < 0.05\) was considered significant. Statistical analysis was performed using IBM SPSS Statistics version 21.0.

**Results**

**Healthy Subjects**

Nine healthy male subjects (mean age 24.3 ±3.0 years) received a single oral administration of the P450-probe cocktail after an overnight fast (control) and after 36 hours of fasting. There were no adverse events.

**Pathomokinetik.** The plasma concentrations versus time profiles in healthy subjects were described using a one-compartment model (caffeine, omeprazole), a two-compartment model (metoprolol, midazolam), and a three-compartment model (S-warfarin; Table 3). Interpatient variability was estimated for clearance and central volume of distribution; intrapatient variability was estimated for clearance.

Despite the study restrictions, preadministration plasma concentrations of caffeine ranging from 0 to 1010 mg/L were observed, which impairs comparison of PK parameters between both interventions. To account for the variable pretreatment intake of caffeine in the PK model, a fictive caffeine dose of 100 mg with variable bioavailability was administered 12 hours before administration of the probe cocktail. The fictive dose of caffeine was used to account for the unknown intake by some of the volunteers. The bioavailability and interindividual variability were parameters estimated in the NONMEM analysis with respective values of 6.7% and 370%. The value of 6.7% indicates that on average predose intake was low, whereas the high variability was caused by two volunteers with predose caffeine plasma concentrations. For omeprazole, nine transit compartments were incorporated in the model to account for the delay between administration and absorption from the gut (Savic et al., 2007). MTT was 1.4 hours, and intraindividual variability in this parameter was 21% (Table 3).

The developed mixed-effects models described the observed data well, as demonstrated by the goodness-of-fit plots shown in Fig. 1. There were no trends in plots of conditional weighted residuals versus time and model predicted concentration (plots not shown). Shrinkage of intra- and interindividual variability of the PK parameters and residual variability was less than 20%. Parameters were estimated with adequate precision; nonparametric bootstraps \(n = 1000\) replicates per model) showed that the final models were robust (Table 3). The validity of the models was further demonstrated by visual predictive checks in which simulated data exhibited a central tendency and variability comparable to the observed data (Fig. 2).

**Effect on PK Parameters.**

**Caffeine (CYP1A2).** Fasting increased oral caffeine clearance (CL/F) by 20% \([\theta_{CL/F, fasting} = 1.20, df = 1, P = 0.03, 95\% \text{ confidence interval (CI)}: 1.03–1.37]\) (Table 3). After post hoc analysis, the median caffeine clearance \([\text{CL/F}_{\text{posthoc}}]\) was 5.6 L/h (range: 3.9–10.7 L/h) in the control study and 7.5 L/h (range: 4.1–17.9 L/h) after 36 hours of fasting. This effect can also be appreciated in the visual predictive check plot (Fig. 2A). S-Warfarin (CYP2C9). Short-term fasting decreased oral S-warfarin clearance by 25% \([\theta_{CL/F, fasting} = 0.75, df = 2, P < 0.001, 95\% \text{ CI}: 0.67–0.83]\), until a time cut point of 23 hours after administration of the cocktail. After post hoc analysis, the median S-warfarin clearance
Twenty-three hours after administration of the drug cocktail, there were no differences in oral S-warfarin clearance. Furthermore, fasting decreased hepatic mRNA expression of CYP2C9 (human orthologs: CYP2D6 and CYP2C19) with 67% (P = 0.001, 95% CI: 0.79–0.90); the corresponding time cut point was 11 hours (Table 3). The effect of fasting on the pharmacokinetics of S-warfarin is demonstrated in the visual predictive check plot (Fig. 2B).

Omeprazole (CYP2C19). Fasting did not affect oral omeprazole clearance (CL/F) nor V_{1/F} in healthy subjects (Table 3; Fig. 2C). Median post hoc estimates for oral omeprazole clearance after the control study and 36 hours of fasting were CL/F_{post hoc} = 34 L/h (range: 18–67 L/h) and CL/F_{post hoc} = 26 L/h (range: 16–81 L/h), respectively.

Metoprolol (CYP2D6). Metoprolol exposure of one subject clearly deviated from the other eight subjects (Figs. 1D and 2D). CL/F was 139 L/h for the typical subject and was 20% lower for the single subject characterized as a CYP2D6 slow metabolizer. Fasting did not affect the pharmacokinetics of metoprolol (Table 3; Fig. 2D). Median post hoc estimates for clearance after the control study and 36 hours of fasting were CL/F_{post hoc} = 114 L/h (range: 28–570 L/h) and CL/F_{post hoc} = 139 L/h (range: 28–545 L/h), respectively.

Midazolam (CYP3A4). Fasting did not affect midazolam (CYP3A4) CL/F or V_{1/F} in healthy subjects (Table 3; Fig. 2E). After post hoc analysis, the median midazolam clearance (CL/F_{post hoc}) in the control study was 92 L/h (range: 46–114 L/h) and 78 L/h (range: 49–122 L/h) after 36 hours of fasting.

**Rats**

Fasting significantly increased hepatic mRNA expression of the nuclear receptors CAR and PXR (Fig. 3, A and B). Furthermore, CL/F_{post hoc} in the control study was 0.18 L/h (range: 0.11–0.27 L/h) and decreased to 0.13 L/h (range: 0.01–0.20 L/h) after 36 hours of fasting.

Twenty-three hours after administration of the drug cocktail, there were no differences in oral S-warfarin clearance. Furthermore, fasting decreased the central volume of distribution by 15% (P < 0.001, 95% CI: 0.79–0.90); the corresponding time cut point was 11 hours (Table 3). The effect of fasting on the pharmacokinetics of S-warfarin is demonstrated in the visual predictive check plot (Fig. 2B).

**Discussion**

This study demonstrates that short-term fasting alters P450-mediated drug metabolism in a nonuniform pattern, but similar for rats and humans. In healthy subjects, short-term fasting increased oral caffeine clearance. This indicates increased activity of CYP1A2, considering that caffeine is a probe of CYP1A2 activity. In accordance, fasting induced hepatic mRNA expression of CYP1A2 by 45% (P = 0.047) and 55% (P = 0.01), respectively (Fig. 3C). Fasting also increased hepatic mRNA expression of CYP2D2 (human orthologs: CYP2D6 and CYP2C19) with 67% (P < 0.001) after 24 hours and 62% (P < 0.001) after 36 hours of fasting (Fig. 3D). A more than doubled expression of mRNA was seen for CYP3A2 (human ortholog: CYP3A4) after 36 hours of fasting: 154% (P < 0.001), and although nonsignificant, 77% (P = 0.24) after 24 hours of fasting (Fig. 3E).

Interestingly, the opposite effect was found for the ortholog of human CYP2C9. Fasting significantly decreased hepatic mRNA expression of CYP2C11 by 42% (P < 0.001) after 24 hours and 58% (P < 0.001) after 36 hours of fasting (Fig. 3F).

**Table 2**

<p>| Effect of 36 hours of fasting on biochemical parameters in healthy male subjects (n = 9) |
|---------------------------------|---------------------------------|---------------------------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Value Median (Range)</th>
<th>Control Median (Range)</th>
<th>Fasting Median (Range)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (cm)</td>
<td>187 (175–194)</td>
<td>187 (175–194)</td>
<td>187 (175–194)</td>
<td>0.018</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>79 (68–88)</td>
<td>79 (68–88)</td>
<td>79 (68–88)</td>
<td>0.007</td>
</tr>
<tr>
<td>Glucose (mmol l^{-1})</td>
<td>5.1 (4.6–5.9)</td>
<td>4.4 (3.6–5.1)</td>
<td>5.1 (4.6–5.9)</td>
<td>0.018</td>
</tr>
<tr>
<td>β-hydroxybutyrate (mmol l^{-1})</td>
<td>0.1 (0.0–0.4)</td>
<td>0.6 (0.3–1.6)</td>
<td>0.1 (0.0–0.4)</td>
<td>0.007</td>
</tr>
<tr>
<td>Acetoacetate (mmol l^{-1})</td>
<td>0.03 (0.01–0.15)</td>
<td>0.19 (0.08–0.33)</td>
<td>0.03 (0.01–0.15)</td>
<td>0.008</td>
</tr>
<tr>
<td>Free fatty acids (mmol l^{-1})</td>
<td>0.50 (0.15–0.91)</td>
<td>1.05 (0.76–1.55)</td>
<td>0.50 (0.15–0.91)</td>
<td>0.028</td>
</tr>
</tbody>
</table>
TABLE 3
PK parameters of the CYP450 probe cocktail in 9 healthy subjects and median parameter values (2.5–97.5 percentile) of nonparametric bootstrap replicates of the final pharmacokinetic models

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Caffeine (CYP1A2)</th>
<th>Metoprolol (CYP2D6)</th>
<th>Midazolam (CYP3A4)</th>
<th>Omeprazole (CYP2C19)</th>
<th>S-Warfarin (CYP2C9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
</tr>
<tr>
<td></td>
<td>Typical value</td>
<td>Typical value</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
</tr>
<tr>
<td>Cl/F (l h(^{-1}))</td>
<td>6.0 (4.6–7.4)</td>
<td>6.1 (5.0–7.8)</td>
<td>139 (78–200)</td>
<td>131 (64–187)</td>
<td>80 (64–96)</td>
</tr>
<tr>
<td>−θ&lt;sub&gt;Cl/F&lt;/sub&gt; Fasting</td>
<td>1.20 (1.03–1.37)</td>
<td>1.23 (1.08–1.39)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>−θ&lt;sub&gt;Cl/F&lt;/sub&gt; Fasting (h)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>−θ&lt;sub&gt;Cl/F&lt;/sub&gt; Slow metabol</td>
<td>—</td>
<td>—</td>
<td>0.80 (0.54–1.06)</td>
<td>0.80 (0.20–1.02)</td>
<td>—</td>
</tr>
<tr>
<td>V&lt;sub&gt;F&lt;/sub&gt; (l)</td>
<td>49 (45–53)</td>
<td>49 (46–53)</td>
<td>536 (430–641)</td>
<td>147 (114–204)</td>
<td>37 (26–49)</td>
</tr>
<tr>
<td>−θ&lt;sub&gt;V/F&lt;/sub&gt; Fasting</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>−θ&lt;sub&gt;V/F&lt;/sub&gt; Slow metabol</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Ka (fixed)</td>
<td>6</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>MTT (h)</td>
<td>—</td>
<td>—</td>
<td>29 (0.6–63)</td>
<td>32 (1.4–283)</td>
<td>40 (23–56)</td>
</tr>
<tr>
<td>—</td>
<td>—</td>
<td>62 (4–119)</td>
<td>66 (25–260)</td>
<td>70 (52–88)</td>
<td>70 (55–91)</td>
</tr>
<tr>
<td>Q&lt;sub&gt;2/F&lt;/sub&gt; (l h(^{-1}))</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Q&lt;sub&gt;1/F&lt;/sub&gt; (l)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Interindividual variability

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Caffeine (CYP1A2)</th>
<th>Metoprolol (CYP2D6)</th>
<th>Midazolam (CYP3A4)</th>
<th>Omeprazole (CYP2C19)</th>
<th>S-Warfarin (CYP2C9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
</tr>
<tr>
<td></td>
<td>Typical value</td>
<td>Typical value</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
</tr>
<tr>
<td>Cl/F (%)</td>
<td>37 (20–50)</td>
<td>37 (21–49)</td>
<td>83 (0–140)</td>
<td>61 (24–110)</td>
<td>31 (15–41)</td>
</tr>
<tr>
<td>V&lt;sub&gt;F&lt;/sub&gt; (%)</td>
<td>11 (2.7–15.6)</td>
<td>9.7 (4.1–14.7)</td>
<td>45 (0–69)</td>
<td>37 (12–63)</td>
<td>39 (0–60)</td>
</tr>
<tr>
<td>Q&lt;sub&gt;2/F&lt;/sub&gt; (%)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Intraindividual variability

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Caffeine (CYP1A2)</th>
<th>Metoprolol (CYP2D6)</th>
<th>Midazolam (CYP3A4)</th>
<th>Omeprazole (CYP2C19)</th>
<th>S-Warfarin (CYP2C9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
</tr>
<tr>
<td></td>
<td>Typical value</td>
<td>Typical value</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
</tr>
<tr>
<td>Cl/F (%)</td>
<td>15 (6.8–20.7)</td>
<td>15 (6.8–20.2)</td>
<td>7.9 (0–12)</td>
<td>8.7 (4.4–16.1)</td>
<td>8.8 (0–13.8)</td>
</tr>
<tr>
<td>MTT (%)</td>
<td>—</td>
<td>—</td>
<td>8.7 (4.4–16.1)</td>
<td>8.8 (0–13.8)</td>
<td>8.6 (3.0–14.0)</td>
</tr>
</tbody>
</table>

Residual variability

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Caffeine (CYP1A2)</th>
<th>Metoprolol (CYP2D6)</th>
<th>Midazolam (CYP3A4)</th>
<th>Omeprazole (CYP2C19)</th>
<th>S-Warfarin (CYP2C9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
<td>Bootstrap</td>
<td>Estimates</td>
</tr>
<tr>
<td></td>
<td>Typical value</td>
<td>Typical value</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
<td>(2.5–97.5%)</td>
</tr>
<tr>
<td>Additional error</td>
<td>6.8 (5.3–8.3)</td>
<td>6.7 (5.0–8.2)</td>
<td>18.0 (7.1–29.1)</td>
<td>17 (9–23)</td>
<td>13 (10–17)</td>
</tr>
</tbody>
</table>

θ, fractional change of the parameter due to fasting; Cl/F, elimination clearance; Ka, absorption rate constant; MTT, mean transit time; Q<sub>2/F</sub>, intercompartmental clearance of peripheral compartment 1; Q<sub>1/F</sub>, intercompartmental clearance of peripheral compartment 2; V<sub>1/F</sub>, volume of distribution of the central compartment; V<sub>2/F</sub>, volume of distribution of peripheral compartment 1; V<sub>3/F</sub>, volume of distribution of peripheral compartment.
CYP2C19, and CYP2D6. However, fasting did not affect the pharmacokinetics of the corresponding P450-probe drugs midazolam, omeprazole, and metoprolol in humans.

This discrepancy may be due to interspecies differences. Although sequence homology of P450 enzymes among species is high, small differences in amino acid sequences at the active sites of P450 enzymes can result in profound differences in isoform-catalyzing metabolism and specificity of the drugs they metabolize (Martignoni et al., 2006). Therefore, fasting may not exhibit the same selectivity for human CYP450 isoforms as for the corresponding rat isoforms. However, our

![Fig. 1. Goodness-of-fit plots of the five P450-probe drugs: (A) caffeine (CYP1A2), (B) S-warfarin (CYP2C9), (C) omeprazole (CYP2C19), (D) metoprolol (CYP2D6), (E) midazolam (CYP3A4). Observed concentrations versus population-predicted (PRED) and individual-predicted (IPRED) concentrations. The closed circles represent the 36 hours of fasting intervention; open circles represent the control intervention. The solid line is the line of identity.](image-url)
results indicate that CYP1A2 and CYP2C11 in male rats may be used to study the effect of fasting on the corresponding enzymes CYP1A2 and CYP2C9 in humans. Another explanation of this discrepancy may be the relatively short period of fasting (36 hours) in relation to the time necessary to induce some of the P450 enzymes. For example, maximum induction of CYP3A is reached after 3 days of rifampicin treatment, which is a powerful inducer of CYP3A4 (Tran et al., 1999).

In addition to a time-dependent induction of P450 enzymes by fasting, the recovery of enzyme activity after a period of either induction or inhibition is also time-dependent (Yang et al., 2008). Four hours after administration of the drug cocktail, a standardized meal was consumed after which P450-enzyme activity will probably return to the nonfasting state. The time course of this recovery may be determined by either de novo synthesis (after inhibition) or degradation (after induction) of the enzymes.

Fig. 2. Visual predictive check plots of the five P450-probe drugs: (A) caffeine (CYP1A2), (B) S-warfarin (CYP2C9), (C) omeprazole (CYP2C19), (D) metoprolol (CYP2D6), (E) midazolam (CYP3A4). The closed circles represent observed data points after 36 hours of fasting. Open circles represent the control observations. The solid (fasting) and dashed (control) lines represent the 10th and 90th percentiles of the simulated data.
enzyme and the persistent effect of fasting (Yang et al., 2008). Because
the turnover half-life of P450-enzymes is relatively long, it is unlikely
that consumption of this meal would have an immediate effect (Yang
et al., 2008). In addition, the elimination half-life of nearly all drugs in
the cocktail is relatively short such that enzyme activity measured by
these probes can be attributed to a reasonably small time frame. For
S-warfarin, we show that the effect of fasting on CYP2C9-mediated
clearance is only present within the first 23 hours after the 36-hour
period of fasting and diminishes when returned to the nonfasting state.
This is approximately 2–3 times the half-life of CYP2C11 (ortholog of
human CYP2C9), which was found to be ~10 hours (Tollet et al.,
1990). Our observations after 36 hours of fasting may therefore be an
underestimation of the alterations in P450-mediated drug clearance in
subjects or patients who have fasted for a longer period of time.

In contrast, the effects of 36 hours of fasting were readily apparent
in the changes in plasma concentrations of glucose, ketone bodies, and
fatty acids. We cannot exclude the possibility that even shorter periods
of fasting alter CYP1A2- and CYP2C9-mediated drug metabolism, as
shown for the probe drugs caffeine and warfarin after 36 hours of
fasting. With respect to biochemical parameters such as fatty acids,
fasting induces a half-maximal response of the total fasting response
already within 24 hours (Klein et al., 1993). Therefore, periods of
fasting shorter than 36 hours, as used in the current study, may already
affect drug metabolism. For example, skipping meals, which is com-
mon among different types of patients, or chronically reduced oral
intake may already influence metabolism. The drug cocktail used has
previously been validated (Turpault et al., 2009). The absence of a PK
interaction between the probes makes this cocktail useful for the in
vivo evaluation of metabolism-based interactions. Because the drug
cocktail was administered orally in this study, the observed differences
in exposure (AUC, area under the concentration versus time curve)
may be a combined effect of fasting on intrinsic clearance (P450
enzyme activity), bioavailability (F), and protein binding, as described
by the well-stirred model of drug metabolism (Benet and Hoener,
2002):

\[
\text{AUC}_{\text{oral}} = \left(\frac{F_{\text{abs}} \times F_G \times \text{Dose}}{f_u \times \text{Clint}}\right)
\]

(F_{\text{abs}}, fraction of administered drug absorbed into the gut wall; F_G,
fraction that gets through the gut wall unchanged; f_u, fraction unbound
drug in plasma).

Based on this model, the observed effect of fasting on the orthologs
of CYP2D6, CYP2C19, and CYP3A4 in rats may also be present in
humans, but was not seen. For metoprolol (CYP2D6) (F \(\leq\) 0.45, f_u =
0.90–0.95), omeprazole (CYP2C19) (F \(\leq\) 0.40, f_u \(\leq\) 0.03), and
midazolam (CYP3A4) (F \(\leq\) 0.45, f_u \(\leq\) 0.03), the effect of fasting on
Clint may be masked if fasting simultaneously changes bioavailability (\(F_{abs} F_{co}\)) or protein binding (Imaoka et al., 1990; Micromedex, 2014). This may also imply that the effects observed for caffeine (CYP1A2) and warfarin (CYP2C9) in humans may not entirely be due to differences in intrinsic clearance, but also due to differences in other parameters in the well-stirred model. However, it is unlikely that fasting affects bioavailability, because for both drugs bioavailability is 100% (F = 1) (Micromedex, 2014). For plasma protein binding, Vorum and Honore (1996) have shown that the binding affinity of warfarin to human serum albumin increased on addition of plasma fatty acids. As we have shown, fasting increased the plasma concentration of fatty acids. Therefore, fasting may increase the already high plasma protein binding of warfarin [fraction bound (\(f_b = 0.99\)], thereby causing a relatively large decrease in the fraction of unbound warfarin (\(f_{UB} = \frac{f_b}{1-f_b}\)) (Imaoka et al., 1990), which reduces observed oral clearance.

The decrease of \(f_{UB}\) may also reduce the observed volume of distribution (V). V is determined by the fraction of unbound drug in plasma (Imaoka et al., 1990) and in tissue (\(v_{T}\)), the volume of tissue (VT), and the volume of plasma (VP) (Wilkinson and Shand, 1975):

\[
V = \frac{f_{UB} f_{T}}{f_{UB} T} V_T + V_P
\]

Assuming that VT and VP remain constant, a decrease in fraction of unbound warfarin in plasma can decrease the volume of distribution, as observed in the present study. In contrast, caffeine has only a limited binding affinity (\(f_b = 0.36\)) to plasma proteins, making the volume of distribution much less dependent on changes in protein binding than warfarin (Micromedex, 2014). Because fasting did not influence the volume of distribution of caffeine, it is plausible to assume that VT and VP remain unaffected. Otherwise, a possible effect on VP, such as the amount of water intake, or VT, resulting in an altered volume of distribution, should probably have been seen. Additional research will be performed to investigate the effect of fasting on protein binding and bioavailability of all studied drugs.

Although the effect of fasting on warfarin (CYP2C9) metabolism may be explained by both increased protein binding and decreased intrinsic clearance, fasting decreased hepatic mRNA expression of the P450 enzyme corresponding to human CYP2C9 in rats. This implies that fasting affects CYP2C9 intrinsic clearance, but in opposite way to the findings for the other P450 enzymes studied, and demonstrates the complexity of the underlying molecular and pharmacological mechanisms. The pathway of P450 enzyme regulation by transcription factors is complex and possibly consists of (multiple) positive and negative feedback loops. Besides PXR and CAR, fasting may affect other transcription factors, such as the aryl hydrocarbon receptor (AhR). The AhR together with the AhR nuclear translocator are primarily responsible for the regulation of the expression of CYP1A1, CYP1A2, and CYP1B1 (Monostory et al., 2009). Fasting may increase AhR/AhR nuclear translocator activity, leading to enhanced CYP1A2 enzyme activity with, as we have shown, increased caffeine clearance.

Differences in nutritional condition by fasting or malnutrition are common among all types of patients. Due to these differences in nutritional states, patients receiving medication at fixed doses may become either under- or overdosed during progression of their disease. In this study, we showed that fasting decreases and increases the exposure to drugs specifically metabolized by CYP1A2 and CYP2C9, respectively. This may be clinically relevant for drugs with a small therapeutic range and/or metabolized by these specific P450 enzymes, such as many antidepressants (e.g., amitriptyline, clomipramine), some atypical antipsychotics (clozapine, olanzapine), flutamide (cytotoxic agent), anticoagulant agents (acenocoumarol, phenprocoumon), phenytoin (anti-epileptic agent), and oral hypoglycemic agents (e.g., tolbutamide, glipizide, and sulfonylureas).

Furthermore, in addition to short-term fasting, longer periods of fasting might also influence three other key P450 enzymes involved in human drug metabolism, as we have shown in rats.

Our findings may imply that dose adjustments of drugs metabolized by P450 enzymes could be necessary to improve drug treatment in patients with fasting-related consequences such as malnutrition or cachexia. Additional research is necessary to reveal the molecular and pharmacological mechanisms underlying our observations, but also prospective studies to test the clinical implications of our findings.

Acknowledgments

The authors thank M. Pistorius for specific contribution to the laboratory analysis of this study. The authors also thank L. Eggels for technical assistance with the animal experiments.

Authorship Contributions

**Participated in research design:** Lammers, Achterbergh, De Vries, Van Nierop, Klümper, Soeters, Boelen, Romijn, Mathôt.

**Conducted experiments:** Lammers, Achterbergh, De Vries, Van Nierop.

**Contributed new reagents or analytic tools:** Lammers, Mathôt.

**Performed data analysis:** Lammers, Achterbergh, De Vries, Mathôt.

**Wrote or contributed to the writing of the manuscript:** Lammers, Achterbergh, De Vries, Van Nierop, Klümper, Soeters, Boelen, Romijn, Mathôt.

References


Address correspondence to: Drs. Laureen A. Lammers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, E-mail: l.a.tenberg-lammers@amc.uva.nl